On the horizon—the value and promise of the global pipeline of Alzheimers disease therapeutics

摘要

The recent failure of several late‐stage Alzheimer's disease (AD) clinical trials focused on amyloid beta (Aβ) highlights the challenges of finding effective disease‐modifying therapeutics. Despite major advances in our understanding of the genetic risk factors of disease and the development of clinical biomarkers, and that not all Aβ‐based approaches are equivalent, these failures may engender skepticism regarding the value of the AD pipeline.